Results 201 to 210 of about 236,446 (302)

Massive fetomaternal hemorrhage and successful prevention of maternal RhD alloimmunization: A case report

Transfusion, EarlyView.
Abstract Background Massive fetomaternal hemorrhage can lead to significant fetal morbidity or mortality. RhD negative patients require appropriate treatment to prevent alloimmunization in subsequent pregnancies. Few cases with follow‐up into future pregnancies have been reported.
Sajjad Hassan, Angela Essa, Lauren Orr, Corina N. Schoen, Chester Andrzejewski   +4 more
wiley   +1 more source

Delayed Recognition of Thrombotic Thrombocytopenic Purpura Following Platelet Transfusion: A Clinical Pitfall. [PDF]

Clin Case Rep
Al-Dawoudi A, Dalain M, Varlamov D, Alhallak S, Freimanis D.   +4 more
europepmc   +1 more source

A global survey of blood transfusion practices for patients with sickle cell disease

Transfusion, EarlyView.
Abstract Background Sickle cell disease (SCD) affects over 7 million people globally, with blood transfusion remaining a cornerstone of management. However, contemporary transfusion practices across diverse settings remain poorly characterized. We evaluated global transfusion practices for patients with SCD to identify gaps and inform resource ...
Jeremy W. Jacobs, Arwa Z. Al‐Riyami, Jeannie Callum, Meghan Delaney, David Daniel, Jenny White, Christopher Bocquet, Mohammed Farouk, Claude Tayou, Chinelo P. Onyenekwu, Kristina Prus, Divjot Singh Lamba, Julie Makani, Quentin Eichbaum, Luiz Amorim, Silvano Wendel, France Pirenne, Vernon Louw, Evan M. Bloch   +18 more
wiley   +1 more source

Breakthrough Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: Mechanistic Insights and Management Strategies

Transfusion, EarlyView.
Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by somatic mutations in the PIGA gene, resulting in loss of glycosylphosphatidylinositol (GPI)‐anchored proteins, including the complement regulatory proteins, CD55 and CD59.
Ganesh Raman, Meghana Vivek, Rida Hasan, Siobán Keel, Laura Connelly‐Smith   +4 more
wiley   +1 more source

Cold agglutinin disease: pathophysiology, diagnosis, and the evolving therapeutic landscape. [PDF]

Blood Res
Choi DH.
europepmc   +1 more source

Pretransfusion testing interference profile of IMC‐002: A novel anti‐CD47 monoclonal antibody engineered for minimized red cell binding

Transfusion, EarlyView.
Abstract Background CD47‐targeted agents can interfere with pretransfusion testing due to CD47 expression on red blood cells (RBCs). IMC‐002 is a novel anti‐CD47 human IgG4 monoclonal antibody engineered to minimize RBC binding; however, its interference profile during pretransfusion testing remains poorly characterized.
Tae‐Shin Kim, Jae Hyeon Park, Yousun Chung, Dae‐Hyun Ko, Seon Young Kim, Hyungsuk Kim   +5 more
wiley   +1 more source

Recognizing thrombotic thrombocytopenic purpura beyond the pentad. [PDF]

Oxf Med Case Reports
Pupiec OM, Levin JR, Cooley CN, Paratore D.   +3 more
europepmc   +1 more source

Molecular characterization of CD36 deficiency in blood donors of Middle Eastern and African origin reveals transcript‐level defects beyond genomic variants

Transfusion, EarlyView.
Abstract Background The increasing diversity of blood donor populations has created new challenges for transfusion services worldwide. The identification of donors lacking relevant high‐prevalence antigens is becoming increasingly important to ensure compatible blood products for alloimmunized patients and to support the development of rare donor ...
Sarah Petermann, Inga Stellmacher, Brigitte K. Flesch, Tanja Rehling, Irina Häcker, Marc F. Schetelig, Alexander Carbol, Lambros Kordelas   +7 more
wiley   +1 more source

Subphenotypes of Sickle Cell Disease: A Guide to Targeting Treatment? [PDF]

Am J Hematol
Steinberg MH.
europepmc   +1 more source

Implementation of soluble CD38 in blood crossmatching for patients on anti‐CD38 therapy: A single‐center experience

Transfusion, EarlyView.
Abstract Background Human monoclonal (MoAb) anti‐CD38 antibodies, such as daratumumab, are used to treat diseases such as multiple myeloma. Because red blood cells (RBCs) express CD38, these MoAbs interfere with antibody screening and crossmatching in blood banks.
Ayda Javanbakht, David Hanna, Grishma Amatya Jaspau, Ravi Sarode   +3 more
wiley   +1 more source